Rifampin has been a cornerstone of tuberculosis (TB) treatment since its introduction. The rise of multidrug-resistant and extensively drug-resistant TB makes the development of novel therapeutics effective against these strains an urgent need. Site-specific mutations in the target enzyme of rifampin, RNA polymerase (RNAP) comprises the majority (~97%) of rifamycin-resistant (Rif R ) strains of Mycobacterium tuberculosis (MTB). To identify novel inhibitors of bacterial RNAP, an in vitro plasmid-based transcription assay that uses malachite green (MG) to detect transcribed RNA containing MG aptamers was developed. This assay was optimized in a 384-well plate format and used to screen 150,000 compounds against an Escherichia coli homolog of the most clinically relevant Rif R RNAP (βS531L) containing a mutation (β′V408G) that compensates for the fitness defect of this Rif R mutant. Following confirmation and concentration-response studies, 10 compounds were identified with similar in vitro inhibition values across a panel of wild-type and Rif R E. coli and MTB RNAPs. Four compounds identified from the screen are active against MTB in culture at concentrations below 200 µM. Initial follow-up has resulted in the elimination of one scaffold due to potential pan-assay interference.
Introduction
Tuberculosis (TB), caused by the pathogen Mycobacterium tuberculosis, is one of the largest global health problems. TB exists in two forms, latent and active, with an estimated onethird of the global population infected with the latent form. There are an estimated 8 to 10 million new cases of TB each year (10.4 million new cases in 2015). TB is one of the leading causes of death worldwide, killing 1.8 million people (1.4 million HIV-negative and 0.4 million HIV-positive) globally in 2015, rivaling HIV-associated deaths (1.1 million) as the leading cause of death from infectious diseases. 1 Global treatment success rates for newly diagnosed TB were 83% in 2014. 2 The current treatment regimen for TB is a 6-to 9-month time course of four different first-line anti-TB drugs: rifampin (RMP), isoniazid, ethambutol, and pyrazinamide. However, there are increasing numbers of cases of drug-resistant TB, with an estimated 480,000 new cases of multidrug-resistant TB (MDR-TB; resistant to RMP and isoniazid) in 2015, of which 10% is estimated to be extensively drug-resistant TB (XDR-TB), having additional resistance to some second-line anti-TB drugs. Globally, only 50% of MDR-TB patients were successfully treated. It is clear that novel drugs are still needed for successful treatment of individuals with MDR-or XDR-TB.
Despite this clear and pressing need, only two TB drugs with novel mechanisms have been introduced in the past 50 years (bedaquiline and delamanid), and MTB strains resistant to both drugs have already appeared in the clinic. 2, 3 Reinvestigating previously effective drug targets has, in some cases, proven to be successful in antibiotic drug discovery. 4, 5 The lack of new drugs effective against MDRand XDR-TB makes developing novel inhibitors of previously successful targets an attractive approach.
RMP, one of the first-line anti-TB drugs, was first introduced in the 1960s and is bactericidal by inhibiting the bacterial DNA-dependent RNA polymerase (RNAP). 6 However, rifamycin-resistant (Rif R ) mutations in the RNAP arise at a high rate (~10 -8 ), necessitating the use of RMP in combination with other drugs to minimize resistance development. 7 Mutations within an 81-bp core region of the rpoB gene, known as the RMP resistance determining region (RRDR), account for ~96% of all Rif R strains of MTB. 7 Mutations at three residues in the RRDR (S450, H445, D435) account for ~84% of Rif R strains, and the most clinically prevalent mutation (S450L) accounts for ~45% of Rif R MTB. These mutations dramatically reduce the affinity of RNAP for rifamycins. 8 This suggests that novel inhibitors of RNAP that bind in sites other than the RRDR should be effective against Rif R TB. To identify novel inhibitors of Rif R RNAP, we sought to perform a high-throughput screen (HTS) of ~150,000 small molecules against the E. coli homolog of the most clinically prevalent Rif R MTB RNAP, βS450L (E. coli βS531L). Recent studies have shown the S450L Rif R mutant to have a fitness defect that in many clinical strains is compensated for by specific secondary mutations in rpoC. 9, 10 The most effective compensating mutation is V483G of the β′ subunit. To reflect what is likely the most prevalent Rif R RNAP in Rif R , MDR-and XDR-MTB, the E. coli RNAP βS531L/β′V408G (corresponding to βS450L/β′V483G in the MTB numbering) was used for the HTS.
Previous screens for inhibitors of RNAP have used radiolabeled or fluorescent nucleotide analogs. 11, 12 Another approach involved detection of the RNAP core enzyme-σ factor interaction (holoenzyme assembly). 13, 14 HTS using nucleotide analogs can be cost prohibitive, or impractical in the case of radiolabeled NTPs, whereas detecting the RNAP-σ interaction could significantly limit the potential modes of RNAP inhibition. Therefore, we developed a robust enzymatic assay in which an inexpensive, commercially available dye (MG) could be used for detection of RNA transcribed by RNAP from a plasmid template ( Fig.  1A) . 15 The product RNA contains repeats of a 38-nucleotide RNA aptamer that binds MG and results in an ~2000-fold increase in MG fluorescence. This assay was used to screen E. coli RNAP βS531L/β′V408G to discover compounds for potential drug development against MDR-and XDR-TB.
Materials and Methods

Reagents
All reagents were purchased from Sigma-Aldrich (St. Louis, MO), unless otherwise specified. Nucleoside triphosphates were purchased from Chem-Impex International (Wood Dale, IL). QIAprep Spin Miniprep Kit, Giga Kit, QIAquick Gel Extraction Kit, QIAquick Nucleotide Removal Kit, and Ni-NTA agarose were from Qiagen (Valencia, CA). Yeast extract, bactotryptone, kanamycin, DTT, Corning microplates, and Amicon Centrifugal Filter Units were purchased from Fisher Scientific (Hampton, NH). Carbenicillin and isopropyl β-D-1-thiogalactopyranoside (IPTG) were purchased from Gold Biotechnology (St. Louis, MO). Chloramphenicol was purchased from Tokyo Chemical Industry (Tokyo, Japan). Taq DNA polymerase, T4 DNA ligase, Antarctic phosphatase, deoxynucleoside triphosphates (dNTPs), and all restriction enzymes were purchased from New England Biolabs (Ipswich, MA). PfuUltra high-fidelity DNA polymerase was purchased from Agilent Technologies (Santa Clara, CA). pCR2.1-TOPO Cloning Kit, Quant-iT RiboGreen RNA reagent, and all synthetic oligonucleotides were purchased from Invitrogen (Carlsbad, CA). Oligonucleotide primers used in this study are listed in Supplemental Table S1 . Plasmids used and prepared in this study are listed in Supplemental Table S2 . The Bio-Rad Protein Assay Kit was purchased from Bio-Rad (Hercules, CA). GELase Agarose Gel-Digesting Preparation was purchased from Epicentre (Madison, WI), and Seaplaque Agarose was from Lonza (Rockland, ME). ProxiPlate-384 Plus F microplates were from PerkinElmer (Waltham, MA). Fresh samples of selected compounds from the HTS were purchased from the vendors listed in Supplemental Table S6 .
Strains and Plasmids
MTB H37Rv and Vero cells (ATCC) were used for minimum inhibitory concentration (MIC) and cytotoxicity assays, respectively. Plasmid construct pVS10 for wild-type (WT) E. coli RNAP expression was a generous gift from Irina Artsimovitch (Ohio State University). The preparation of pVS10 E. coli RNAP expression plasmids for β subunit mutations D516V, H526Y, S531L was previously described. 16 The pU6+19 vector containing the four MG aptamer (MGA) repeats (pU6+19-4xMGA) was a generous gift from Dr. Marit Nilsen-Hamilton (Iowa State University). 17 The pFPV27-prrn plasmid was a generous gift from Dr. Jaya Tyagi (India Institute of Medical Sciences). 18 Other plasmids used in this study were prepared as described below.
Small-Molecule Library
A 150,554 compound library was screened at the Center for Chemical Genomics (CCG; University of Michigan, Ann Arbor). The library consisted of compounds from the Chemical Diversity set (120,000 compounds), Maybridge HitFinder, MicroSource Spectrum, and NCC BioFocus libraries.
Construction of Reporter Plasmid
The construction and optimization of the reporter plasmid is described in the supplemental material.
RNAP Expression Vectors
An expression plasmid for E. coli S531L RNAP with the compensatory mutation β′V408G was prepared from the expression plasmid pVS10(S531L) as follows. The wildtype E. coli rpoC gene was amplified from pVS10 using oligonucleotides ECrpoC-Fwd and ECrpoC-Rev and subcloned using the TOPO Cloning Kit (pCR2.1-TOPO). The compensatory mutation V408G (GTT-GGT) was introduced to rpoC via two-stage site-directed mutagenesis with complementary oligonucleotides ECrpoCMut-Fwd and ECrpoCMut-Rev. The mutant rpoC gene and pVS10 (S531L) were restricted with SbfI and SacII and ligated with T4 DNA ligase to prepare pVS10 (S531L/V408G). Expression vector pET15b-Sig70 used for expression of E. coli σ 70 was previously prepared (V. Molodtsov and K. S. Murakami, unpublished data).
MTB RNAP expression vectors pACYCDuet-rpoA-rpoZ and pETDuet-rpoB-rpoC were prepared using the same approach as used by Banerjee et al., 19 amplifying and inserting the MTB genes using appropriate primers and restriction enzymes (Suppl . Table S1 ) from a construct previously prepared in our lab (pMTBRP-5). 16 The sigA gene encoding MTB σ A was amplified from genomic DNA of MTB H37Rv using oligonucleotides MTBsigA-Fwd and MTBsigA-Rev. pRSF-SigA was then prepared by restricting the sigA PCR fragment and pRSFDuet-1 with NcoI and MfeI, followed by phosphatase of pRSF vector and ligation of the sigA gene and pRSF vector. Expression vectors for mutant RNAPs (D435V, H445Y, S450L) were prepared by amplifying the mutant rpoB genes from previously prepared constructs (pMTBRP-6 through -8) and inserting into pETDuet-rpoB-rpoC using the restriction enzymes NcoI and BamHI. 16 The expression plasmid for MTB βS450L/β′V483G RNAP was prepared by mutating the rpoC gene subcloned in a TOPO vector to encode V483G (GTG-GGC) via two-stage sitedirected mutagenesis using complementary oligonucleotides MTBrpoCMut-Fwd and MTBrpoCMut-Rev and then inserting into pETDuet-rpoB(S450L)-rpoC. pMCSG7-SigA was prepared previously. 20 
Expression and Purification of E. coli and MTB RNAPs
Expressions and purifications of E. coli and MTB RNAPs were conducted as previously described, 21 with a few modifications as described in the supplemental material.
Expression and Purification of
were grown in 3 L 2xTY at 30 °C until OD 600 ~ 0.5, then induced with 1 mM IPTG and allowed to grow for an additional 2 h at 22 °C. Cells were harvested by centrifugation and resuspended in 30 mL σ 70 lysis buffer (20 mM Tris-HCl, 0.4 M NaCl, 1 mM EDTA, 2 mM phenylmethane sulfonyl fluoride [PMSF], 5 mM β-ME, 5% glycerol, pH = 8.0 at 4 °C) and then sonicated on ice. The lysate was cleared by centrifugation (35,000g, 30 min, 4 °C), and the supernatant (30 mL) was applied to a 10-mL Ni 2+ column equilibrated with σ 70 lysis buffer + 20 mM imidazole and then washed with 20 column volumes (CVs) of the same buffer. Protein fractions (25 mL) were eluted with 50-mL σ 70 elution buffer (10 mM Tris-HCl, pH 8.0 at 4 °C, 200 mM NaCl, 5% glycerol, 0.1 mM EDTA, 5 mM β-ME, 200 mM imidazole). Next, the protein was diluted to reduce the concentration of NaCl to 100 mM and applied to a 5-mL Q Sepharose column equilibrated with σ 70 elution buffer (without imidazole) and a linear gradient of 0.1 to 0.6 M NaCl over 20 CVs. Fractions containing σ 70 were determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, combined together (60 mg in 20 mL), and flash frozen in liquid N 2 until further use.
Expression and Purification of MTB σ A
E. coli BL21(DE3) containing pMCSG7-SigA were grown in 2 L 2xTY at 37 °C until OD 600 = 0.4 to 0.6, then expression was induced with 1 mM IPTG and grown at 16 °C for 16 to 20 h. Cells were pelleted and resuspended in σ 70 lysis buffer and supplemented with 2 mM PMSF. Cells were sonicated, and lysate was cleared by centrifugation (21,000g, 40 min, 4 °C). Supernatant was incubated with 2-mL Ni-NTA agarose and incubated at 4 °C with shaking for 1 h. The mixture was then applied to a column and washed as follows: 5 CVs, σ 70 lysis buffer; 8 CVs, σ 70 lysis buffer + 15 mM imidazole; 10 CVs, σ 70 lysis buffer + 100 mM imidazole. Eluted protein was concentrated using a 10 kDa MWCO Amicon Ultra-15 Centrifugal Filter Unit, filtered, and applied to a HiPrep 16/60 Sephacryl S-200 HR equilibrated with TGED containing 200 mM NaCl. Protein was pooled and concentrated and then flash frozen and stored at −80 °C. Protein can be stored as is or containing glycerol (final concentration of 25% glycerol was used).
In Vitro Transcription Assay
The activity of E. coli RNAP was measured via plasmidbased, in vitro transcription using pMGA12. A 50 µL reaction was prepared in Corning 96-well half-area black flat-bottom polystyrene NBS microplates. In each well, 24 µL of a 2x E. coli reaction buffer solution (80 mM Tris-HCl [pH = 7.5 at 23 °C], 100 mM KCl, 20 mM MgCl 2 , 0.02% Triton X-100, 16 mM DTT, 20 nM pMGA12, 1 mM NTPs) was added, 2 µL of DMSO or compound in DMSO, followed by 24 µL of a 2x RNAP solution (80 nM RNAP, 240 nM σ 70 ). Reactions were incubated at 37 °C for 2 h then halted by incubating on ice and adding 50 µL of cold 60 µM MG in water. After 5 min on ice, MG fluorescence was detected at excitation and emission wavelengths of 628 nm and 660 nm, respectively. MTB RNAP transcription assays were done the same as E. coli RNAP; however, the following 2x MTB reaction buffer solution was used: 40 mM Tris-HCl (pH = 8.0 at 37 °C), 20 mM MgCl 2 , 300 mM potassium L-glutamate, 15% glycerol.
High-Throughput Bacterial Transcription Assay
The transcription assay described above was modified to 384-well plate format, with a reaction volume of 20 µL. A 2x E. coli reaction buffer was added (10 µL) to each well of 384-shallow well microplates (ProxiPlate-384 Plus F) using a multidrop dispenser (Thermo Scientific, Waltham, MA). Compounds or DMSO were then added (20 µµM final, n = 1, 0.2 µL) to the appropriate wells using a Biomek FX HDR pintool instrument (Beckman, Fullerton, CA). TGED containing 50 mM NaCl and 0.01% Triton X-100 was added (10 µL) to the appropriate wells for a positive control via multidrop dispenser. A 2x RNAP solution (80 nM βS531L/β′V408G E. coli RNAP core, 240 nM E. coli σ 70 in TGED containing 50 mM NaCl and 0.01% Triton X-100 was added to the appropriate wells (10 µL) via multidrop dispenser for a reaction volume of 20 µL. The plates were incubated at 37 °C for 2 h and then placed on ice for 10 min. A solution of 150 µM MG was added (5 µL) to each well. The plates were incubated on ice for 10 min before measuring fluorescence in an EnVision Multilabel plate reader (PerkinElmer) using a Cy5 620/10 filter for excitation and a LANCE 665/7.5 filter for emission.
Confirmation and Counterscreens
Compounds identified from the primary HTS were tested against a series of control screens. First, compounds were retested (n = 3) in the assay following the protocol above, except compounds were added to empty plates using a mosquito X1 (TTP Labtech) prior to addition of buffer and RNAP solutions. These compounds were also tested for interference of MG•MGA fluorescence. This was done by adding 20-µL of preformed RNA (1x E. coli reaction buffer solution and 1x E. coli RNAP solution incubated at 37 °C for 2 h) into plates containing the compounds, followed by addition of MG (5 µL, 150 µM). After 10 min on ice, the fluorescence was measured at excitation and emission wavelengths of 620 and 665 nm, respectively (EnVision plate reader). Compounds that reconfirmed and did not inhibit MG•MGA fluorescence were tested for concentrationdependent inhibition. For the concentration-response study (n = 2), the concentration of the compounds was varied using two-fold serial dilutions (0.78-100 µM final) and tested following the screening protocol described above, adding the compounds to empty plates using the mosquito X1.
Reconfirmation of Hits
Fresh samples of compounds identified as hits were ordered from commercial vendors for a reconfirmation concentrationresponse study. This study was done in the same format as the initial concentration-response study, testing the fresh compounds for activity against E. coli βS531L/β′V408G RNAP. The fresh compounds were then tested against a panel of E. coli and MTB RNAPs (10 total, see Suppl. Table S5 ). The compounds were tested against each enzyme using the screening protocol above (using 2x MTB reaction buffer for MTB RNAPs). Two-fold serial dilutions of compounds were dispensed in duplicate from a mother plate using the pintool device. The mother plate concentrations ranged from 20 to 0.01 mM, giving final compound concentrations of 200 to 0.1 µM in the transcription reactions.
Data Analysis
Active compounds from the initial HTS were defined as compounds that decreased fluorescence signal more than or equal to three times the standard deviation of the negative controls (all analyses were calculated on a plate-by-plate basis) and resulted in greater than or equal to 20% fluorescence inhibition. Compounds that the National Institutes of Health does not allow in their screening collection due to reactivity or known toxic substituents (black flags) 22 and compounds with chemical motifs that tend to be highly reactive or highly toxic and nonspecific (red flags) were excluded. Compounds that hit in more than 30% of screens previously run at the CCG were also excluded. Compounds that passed these initial selection criteria were retested (n = 3) and screened for false-positives resulting from inhibition of fluorescence of MGA-bound MG. Compounds that inhibited fluorescence of MGA-bound MG (n = 3) more than 25% were excluded. (Note that two rows on each plate used a less stringent cutoff of 45% fluorescence inhibition because of a partial clog in one tube of the multidrop dispenser cassette, resulting in a lower average fluorescence for these wells.) Remaining compounds with fluorescence inhibition more than or equal to three times the standard deviation of the negative controls in at least two wells (n = 3) were tested for concentration-dependent inhibition. Compounds that inhibited E. coli βS531L/β′V408G RNAP in a concentration-dependent manner (determinable IC 50 or displayed concentration-dependent trend) were considered hits from the HTS. Data were fit by nonlinear regression to Eq. (1), where M0 = log of compound concentration, M1 = log of IC 50 , M2 = hill slope, M3 = lower limit of the curve, and M4 = upper limit of the curve. 
Fluorescence Intercalator Displacement Assay
Binding of compounds to DNA was determined by fluorescence intercalator displacement (FID). A 60 bp FID-lacUV5 probe was used for this study. The FID-lacUV5 probe was hybridized by mixing the top and bottom oligonucleotides (Suppl. Table S1) 1:1 after suspending in TE/NaCl buffer (10 mM Tris-HCl, 1 mM EDTA, 50 mM NaCl, pH = 8.0). The top and bottom oligonucleotides were annealed in a thermocycler by heating at 94 °C for 2 min, followed by 70 °C for 2 min, and then were allowed to slowly cool to room temperature. The assay was conducted in triplicate as previously described. 23 
MICs and Cytotoxicity
The MICs of compounds against MTB were determined using MTB H37Rv in a microplate alamar blue assay (MABA) and low-oxygen recovery assay (LORA) as previously described to test the compounds against replicating and nonreplicating bacteria, respectively. 24 The cytotoxicity of the compounds was determined against Vero cells using an MTS assay, as previously described. 25 
Results
Development and Validation of Transcription Assay
The pMGA12 plasmid construct was optimized to give a robust signal using an inexpensive detection reagent (MG), so that it was amenable to HTS. To enhance the signal from the initial construct (pTZ18U-4xMGA), several modifications to the plasmid were made (Suppl. Fig. S1 ). Additional MGA repeats were inserted to increase the signal, a strong promoter (lacUV5) was used to increase the activity of the enzyme, and portions of the plasmid were removed to minimize the transcription of the plasmid sequence that did not contain the aptamer as well as decrease the mass of plasmid required for the HTS. Highly purified RNAP shows no detectable nuclease activity, eliminating the need for nuclease inhibitor in the HTS reactions. The activities of the RNAPs in this study were determined to be linear across the time course of the assay (Suppl. Fig. S2) . After optimizing the assay for a high-throughput format using a 384-well plate, a Z′ of 0.78 was calculated, indicating the assay is robust for HTS.
Hit Identification
A summary of the triage of the HTS is shown in Figure 2 . The primary screen identified 1738 compounds that met the initial selection criteria (1.2% hit rate). The average Z′ per plate in the primary screen was calculated to be 0.86. The 1738 compounds were then retested in triplicate in the screening assay and also for direct inhibition of MG•MGA fluorescence. Of the 1738 compounds, 396 compounds replicated the screening assay results in triplicate (~25% reconfirmation); however, 89 of these compounds were removed from consideration because they directly inhibited the MG•MGA fluorescence. This yielded 307 compounds, which were tested further. The confirmation and control screening identified 234 of the 307 compounds that displayed concentration-dependent inhibition of transcription, with 190 compounds having a determinable IC 50 (<100 µM, the highest concentration tested; Suppl. Fig. S3A ).
Further elimination based on potential toxicity and chemical novelty (70 compounds), redundancy (80 compounds), and commercial availability (21 compounds) resulted in the selection of 63 compounds that fall into 18 different structural scaffold clusters for reconfirmation.
Reconfirmation
Fresh samples of the 63 compounds were purchased and retested for activity. Of the 63 compounds, 30 compounds were inactive against E. coli βS531L/β′V408G RNAP; however, 27 of the inactive compounds are members of structural clusters, which contain active analogs. To retain chemical diversity within the scaffold clusters, we elected to eliminate only the three inactive compounds that were not in such clusters. This yielded 60 compounds, which were then tested for activity against a panel of E. coli and the corresponding MTB RNAPs: WT, three different Rif R mutants (βD516V, βH526Y, βS531L; E. coli numbering) as well as the double mutant with a compensatory mutation (βS531L/β′V408G), which was the target of the HTS. The IC 50 values of the compounds against these RNAPs ranged from 5 µM to >200 µM, with the majority of the compounds having similar values across the RNAP enzymes tested. The IC 50 values for the most active compounds against each enzyme are in Supplemental Table S5 . Example IC 50 plots are shown in Supplemental Figure S3B . After reconfirmation, a set of six analogs of one scaffold of interest was purchased and tested for inhibition against WT E. coli RNAP as described above. IC 50 values for these compounds are listed in Table 1 .
MICs and Cytotoxicity
Compounds with IC 50 values less than 50 µM against at least one RNAP (18 compounds) were tested for inhibition of replicating (MABA) and nonreplicating (LORA) MTB. Of the compounds tested, only four compounds exhibited detectable growth inhibition at concentrations lower than 200 µM ( Table 2 and Suppl. 
FID Assay
Compounds active against E. coli or MTB RNAP in vitro were each tested at four different concentrations (12.5-100 µM) using the FID assay to determine if the compounds potentially inhibit RNAP by binding DNA. Berenil (diminazine aceturate), a known minor groove binder, was used as a control for assay validation. 26 Three of the compounds inhibited fluorescence of ethidium bromide in the FID assay at 100 µM (one of them had some inhibition at 50 µM also) using the FID-lacUV5 probe (Suppl. Fig. S4 ). However, these compounds also inhibited the fluorescence of ethidium bromide when using a scrambled DNA sequence (data not shown), indicating that the binding is not sequence specific. For reasons discussed below, even though these compounds displace ethidium bromide, it seems likely that their inhibition of RNAP is not caused by binding to the DNA.
Discussion
MTB RNAP is a well-validated target for the treatment of TB; however, target-based mutations conferring resistance to RMP have resulted in a large number of Rif R strains in clinical isolates. The majority (~96%) of Rif R isolates have site-specific mutations in a 27 amino acid region of RNAP where RMP binds (RRDR). The potent sterilizing activity (i.e., bactericidal against both active and latent MTB) of RMP against WT MTB indicates that RNAP is still a promising target for the treatment of Rif R MTB if the rifamycin (Rif) resistance can be circumvented. Previous assays to identify novel inhibitors of bacterial RNAP have used nonnative substrates, which can be cost prohibitive for HTS. 11, 12 An assay amenable to HTS using the commercially available RiboGreen has been reported; however, in addition to the cost associated with the RiboGreen dye, it requires removal and purification of RNA from the DNA template since RiboGreen fluorescence is enhanced by binding to DNA as well as RNA. 16 An assay has been developed that monitors the increase in fluorescence of MG upon binding to an RNA aptamer specific for triphenylmethane dyes. 27 The MGA has been applied to detection of E. coli RNAP activity via rolling circle transcription of a small, circular, single-stranded DNA template. 15 We adapted this approach to use the aptamer for detection of RNA transcribed from a double-stranded DNA template. Obtaining quantities of MTB RNAP sufficient for an HTS has been prohibitive. However, the E. coli RNAP can be obtained in sufficient quantities, has greater activity, and is more stable than the MTB RNAP. We have shown that the E. coli RNAP is a reasonable model for the MTB RNAP, 16 and we have solved the X-ray crystal structure of the E. coli RNAP alone and in complex with Rif derivatives that we have designed. 21 This provides us the potential to determine the three-dimensional structure of the RNAP complex with any novel RNAP inhibitor that we find that has sufficient affinity. An HTS of 150,554 small molecules was then carried out against E. coli RNAP βS531L/β′V408G (Fig. 1B) using the aforementioned plasmid-based in vitro transcription assay. As discussed in the Results section and shown in Figure 2 , the concentration response, control screening, and triage for potential toxicity, novelty, redundancy, and commercial availability resulted in the selection of 63 compounds for reordering. The fresh samples were screened against a panel of E. coli and the corresponding MTB RNAPs: wild-type, three different Rif R mutants (D516V, H526Y, S531L; E. coli numbering), and the double mutant (βS531L/β′V408G). The IC 50 values of the compounds against these RNAPs ranged from 5 to >200 µM (data not shown). With the exception of cluster 6, discussed below, we selected scaffolds that do not show any large (>10-fold) differential in IC 50 values across the panel of WT and Rif R RNAP mutants tested, as these would seem to be more promising as they are likely to be binding outside of the RRDR, hence lacking cross-resistance with Rif R RNAPs.
Encouragingly, 9 of the 63 compounds ( Table 3) had similar IC 50 values across the panel of RNAP enzymes tested, indicating that they are active against Rif R mutants. However, only two of these compounds were active against 28 To determine if this scaffold is indeed a false-positive because of PAINS, a set of six analogs of cluster 1, with and without a nitrile at position R 4 , were purchased, and IC 50 values were determined with WT E. coli RNAP. All of the analogs tested that lacked a nitrile group on the pyrimidine ring were inactive ( Table 1) . Based on these results, it was concluded that this scaffold was not worth pursuing further.
Another group of compounds ( Table 4 , cluster 6, pyrazolopyrimidines) showed comparable activity across most of the E. coli RNAPs with the exception of H526Y. A recent crystal structure of E. coli H526Y RNAP shows significant conformational changes in the Rif binding pocket relative to the WT, D516V, and S531L RNAPs (V. Molodtsov et al., unpublished data) This suggests that these compounds may bind in the Rif binding pocket, but their much smaller size relative to RMP allows them to bind to the D516V and S531L Rif R mutants. As precedence, Xu et al. 29 showed that E. coli H526Y RNAP had complete resistance to the RNAP inhibitor sorangicin A while mutants D516N and S531F, and other residues, showed only partial or no resistance.
Two of the four compounds in cluster 6 (186618 and 193157) showed activity against MTB in culture ( Table 2) . Interestingly, compound 193157 was active in culture despite being inactive against WT MTB RNAP in vitro. It is possible that the activity of 193157 against MTB is due to off-target or nonspecific activity. However, it is known that MTB does metabolize a number of drugs to more active forms 30, 31 ; therefore, our compound may be metabolized (e.g., reduction of the nitro) to an active, RNAP-inhibiting derivative. Compound 186618 was active against all RNAP enzymes tested and active against replicating and nonreplicating MTB. This compound has been synthesized, and the structure and purity were confirmed (R. Rowlands and A. White, unpublished) and found to exhibit very low activity, similar to other cluster 6 analogs. We suspect that the purchased sample of 186618 was contaminated with something that was responsible for the activity. This is under investigation. Two compounds that have higher activity against MTB RNAPs relative to E. coli RNAP ( Table 3) were identified. Compound 257177 is in the same cluster as 123513 ( Table  3 , cluster 4) but has a significantly different activity profile. Compound 257177 is ~10-fold less active against E. coli RNAP than 123513. We cannot make any significant correlations between the structures and activities of these two compounds; however, these differences are noteworthy for potential future structure activity relationship studies in optimizing activity for MTB (or E. coli) RNAP. Compound 145060 showed no significant activity against E. coli RNAP in the follow-up assays and only modest activity against MTB RNAPs (>50 µM).
In this report, we have described an efficient method for detecting transcription of bacterial RNAP from a plasmid template that is suitable for HTS (Z′ = 0.86). Using this novel assay, we identified a set of 15 compounds from seven different structural scaffolds that exhibited promising activity against E. coli and/or MTB RNAP for further investigation. Chemoinformatic analysis and follow-up experiments allowed us to eliminate one scaffold due to likely pan assay interference (PAINS). Ten of the 15 compounds (see Suppl. Table S5 ) exhibited very similar activity against WT and Rif R RNAPs, providing proof of principle that novel RNAP inhibitors can be found that are insensitive to the Rif R mutations. Four of the 15 compounds inhibited growth of MTB in culture at concentrations less than 200 µM, indicating that they can effectively penetrate the MTB cell envelope, providing further proof of principle. While the in vitro activities of these analogs are very modest (low micromolar at best), these compounds represent an initial SAR probe using only commercially available analogs of the HTS hits. A "hit-to-lead" campaign involving iterative design, synthesis, and testing will very likely identify much more potent inhibitors of WT and Rif R MTB RNAP. We should also note that the robust nature of this assay and the potency of RMP for the WT RNAP make it attractive to screen natural product extract libraries with this assay, where compounds of greater chemical complexity and potentially higher affinity may be found.
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